Targeted therapy proves effective against aggressive rare blood cancer

Wednesday, April 24, 2019 - 18:00 in Health & Medicine

Clinical study treating BPDCN with tagraxofusp led to first FDA approval for the disease.

Read the whole article on Science Daily

More from Science Daily

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net